Review on breast cancer immunotherapy


Review on breast cancer immunotherapy


Selamawit Fentahun Ali

School of Veterinary Medicine, Wollo University


American Journal of Cancer Research and Reviews

Cancer immunotherapy consists of approaches that modify the host immune system, and/or the utilization of components of the immune system for treatment and prevention of cancer. Eventhough breast cancer has historically not been considered a favorable target for immunotherapies as compared to those solid tumors such as melanoma and renal cell carcinoma, several preclinical and clinical studies have provided important insights and clinical data that support its potential to improve clinical outcomes for patients with breast cancer. In addition, the recent definition of tumor-specific immunity in breast cancer patients and the identification of several breast cancer antigens has generated enthusiasm for the application of immune based therapies to the treatment of breast malignancies. In general, immunotherapies can be considered either non-specific, such as cytokine, or tumor specific for example a vaccine that targets breast cancer tumor antigens. Current immunotherapeutic approaches either through immunization of the patient (e.g., by administering a cancer vaccine), in which case the patient’s own immune system is trained to recognize tumor cells as targets to be destroyed, or through the administration of therapeutic antibodies as drugs, in which case the patient’s immune system is recruited to destroy tumor cells by the therapeutic antibodies, Cell based immunotherapy is another major entity of cancer immunotherapy. The review concluded that immunotherapeutic approaches combined with novel sequences of chemotherapies, radiation, and immunomodulating agents hold promise for enhancing the treatment of breast cancer.


Keywords: immunotherapy, monoclonal antibodies, cytokine, breast cancer, immune system and cancer vaccines.

Free Full-text PDF


How to cite this article:
Selamawit Fentahun Ali.Review on breast cancer immunotherapy. American Journal of Cancer Research and Reviews, 2020,4:11


References:
1. Dzivenu O, Donnell-Tormey J. Cancer and the immune system. Cancer Research Institute 2003.
2. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011; 121(10):3797–3803.
3. Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee , et al. Tumor infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol.2011; 29: 1949–1955. [PubMed]
4. Dilliman RO. Cancer Immunotherapy. cancer biotherapy and radiopharmaceuticals 2011; 26:1
5. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. Journal for ImmunoTherapy of Cancer 2013; 1:12, 1-12.
6. Soliman H. Immunotherapy Strategies in the Treatment of Breast Cancer. Research on immunotherapy for breast cancer appears promising 2013; 20:17-21.
7. Arens R, Hall TV, Burg SH, etal. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.Seminars in Immunology. 2013; 25: 182– 190.
8. The New Zealand Breast Cancer Foundation (2011). Breast Cancer in New Zealand (Pamphlet). Auckland.
9. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010; 9:75.
10. Sabel MS, Nehs MA. Immunologic approaches to breast cancer treatment. Surg Oncol Clin N Am .2005; 14: 1–31.
11. Fioretti D, Iurescia S, Fazio VM, Rinaldi M: DNA Vaccines: Developing New Strategies against Cancer. Journal of Biomedicine and Biotechnology 2010, :1-16
12. Mortenson ED, Fu. YX. Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Curr Pathobiol Rep .2013; 1:37–42.
13. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491-4497
14. DeMore NK, (2013) Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma.UNC Health Care and UNC School of Medicine,News room.
15. Oshima T, Sato S,et al. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Molecular Cancer .2013; 12:60.
16. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Molecular Cancer .2011; 10:3.
17. Schlom J: Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012; 104:599-613.
18. Jackson E, Soliman H. Realizing the promise of breast cancer vaccines .Vaccine: Development and Therapy 2012; 2: 35–41.
19. Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011; 17(22):7164–7173
20. Gilewski T, Adluri S,et al. Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21. Clin Cancer Res .2006 ; 1693
21. Armstrong AC, Gilham DE. Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein. Breast Cancer Research .2012; 14:106.
22. Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER’s-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01and I-02. Cancer. 2012; 118(10):2594-2602.
23. Abe H, Shimamoto T,et al. Targeted Cancer Therapy by Dendritic Cell Vaccine. 2013; 300-317.
24. Dimberu PM, Leonhardt RM. Cancer Immunotherapy Takes a Multi-Faceted Approach to Kick the Immune System into Gear. Yale J Biol Med. 2011; 84(4): 371–380.
25. Feng.X.Cell-Based Immunotherapy for Cancer Treatment.US Pharm.2013;38(9) (Oncology suppl):8-11
26. Standish LJ, Sweet ES,et al. Breast Cancer and the Immune System. J Soc Integr Oncol. 2010; 6(4): 158–168.
27. Geng Y, Chandrasekaran S, Hsu J-W, Gidwani M, Hughes AD, et al. (2013) Phenotypic Switch in Blood: Effects of Pro-Inflammatory Cytokines on Breast Cancer Cell Aggregation and Adhesion. PLoS ONE 8(1): e54959
28. Goldberg JE, Schwertfeger KL.Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.Curr Drug Targets. 2010 Sep; 11(9):1133-46.
29. Rao VSR, Dyer CE, et al. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncology reports .2006; 15: 179-185.
30. Lee S, Margolin K. Cytokines in Cancer Immunotherap y. Cancers ;2011:3, 3856-3893.